In case you missed it: December 4 to December 9
A look back at this week's news.
Exploring Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
Michael L. Krychman, MD, and Jack D. Sobel, MD, review the mechanisms of ibrexafungerp and how it might fit in the treatment spectrum for RVVC.
Impact of state mandatory IVF insurance coverage
State infertility insurance mandates are critical for improving access to infertility care. They also help to advance gender equality and reproductive rights.
IVF for women with previous recurrent ectopic pregnancy
Women with previous recurrent ectopic pregnancy (EP) have a significantly lower risk of EP following in vitro fertilization (IVF), compared to women with previous single EP, according to a retrospective cohort study published in the journal PLOS One.
Uterine anomalies in pregnancy
Clinical pearls for assessment and management of the pregnant patient with a uterovaginal anomaly.
Leadership in the new reality
Although leadership in our post-pandemic climate is probably no more challenging than at any other time, it certainly feels that way.
Pre-Roe abortion services and trends in US
Investigators conducted a study to gather a baseline assessment of abortion incidence and service delivery prior to Roe v Wade being overturned earlier this year.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
